Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 3 - License Supplier Agreement (Details Textual)

Note 3 - License Supplier Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended	4 Months Ended
	Sep. 26, 2023	Apr. 27, 2023	Mar. 30, 2023	Feb. 28, 2023	Oct. 29, 2018	Dec. 31, 2019	Mar. 31, 2023	Jun. 17, 2015
Contractual Obligation Development Expense						$ 81,500
Contractual Obligation, Commercial Expense						$ 151,000
Stock Issued During Period, Value, License Expense							$ 1,231
AnnJi [Member]
License Agreement, Purchase Consideration				$ 3,000
Payments to Acquire License		$ 2,000
Acquired License Payable Within 180 Days				1,000
Maximum Reimbursement Amount In Connection With Product Clinical Trial				10,800
Maximum Reimbursement Amount In Connection With Certain Development Milestones				14,500
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone				27,500
Maximum Reimbursement Amount Upon Achievement of Sales Milestone				165,000
Stock Issued During Period, Shares, License Expense (in shares)			11,089
Stock Issued During Period, Value, License Expense			$ 900
Stock Issuable During Period, Shares, Upon Enrollment of Patient (in shares)	3,688
Stock Issuable During Period, Value, Upon Enrollment of Patient	$ 300
AnnJi [Member] \| Minimum [Member]
Sales Milestone Required for Maximum Reimbursement				75,000
Annual Sale Threshold for Royalty Payment				50,000
AnnJi [Member] \| Maximum [Member]
Sales Milestone Required for Maximum Reimbursement				750,000
Annual Sale Threshold for Royalty Payment				$ 300,000
Revogenex License [Member]
Contractual Obligation, Maximum Future Payments								$ 3,000
Baergic Licenses [Member] \| CCHMC [Member]
Percentage of Equity Fee						5.00%
Polpharma [Member]
Payments to Acquire in Process Research and Development					$ 2,000
Fortress Biotech Inc [Member] \| Iv Tramadol [Member] \| Upfront Payment [Member]
Payments to Acquire in Process Research and Development								2,000
Percentage of Equity Fee						20.00%
Fortress Biotech Inc [Member] \| Iv Tramadol [Member] \| Additional Payment [Member]
Payments to Acquire in Process Research and Development						$ 1,000		$ 1,000
Baergic Licenses [Member] \| Upfront Payment [Member] \| CCHMC [Member]
Payments to Acquire in Process Research and Development						200
Baergic Licenses [Member] \| Upfront Payment [Member] \| AZERBAIJAN
Payments to Acquire in Process Research and Development						$ 3,000
AnnJi [Member]
Right to Sell Common Stock, Price Per Share (in dollars per share)	$ 2.1